Ann: Notice of Extraordinary General Meeting/Proxy Form, page-67

My theory is that some had early knowledge of the human trials and drove the price up however the release of the 4C was a massive reality check for all and now investors realise the big +ve of human trials is more than offset by the big -ve of an impending capital raise (probably at a discount... yet again).

I'm starting to think a group of us should get together and put a few proposals to Patto. @lexcorp was nice enough to share that immunotherapies was offloaded to Finlayson for $300k (now Jingang Medicine), surely 10
of us could have gotten together and offered $300,001 (or even $500k). With some clever marketing/equity crowd funding I reckon another $300k-500k could
have been raised to allow Frazer to continue research/development).

I'm seriously questioning whether Patto "has shareholders best interests" in mind with each decision he makes. Once again I feel like the ultimate owner (read acquirer) of the Adapt tech will end up with far more value than current (retail) shareholders...